DrugPatentWatch

Competitive intelligence on small-molecule drugs and the 80,000 patents covering them

Simple flat-rate subscription plans

Ultimate Plan

$495/ month or  $2,495/ year

Tradename: NAPRELAN

Summary for Tradename: NAPRELAN

Patents:1
Applicants:1
NDAs:1
Suppliers: see list9
drug
patent expirations by year for
 NAPRELAN

Pharmacology for Tradename: NAPRELAN

Clinical Trials for: NAPRELAN

A Study to Determine the Effect of Sumatriptan and Naproxen Sodium Combination Tablet, Sumatriptan Tablet, and Naproxen Sodium Tablet on Blood Pressure When Treating Migraine Headaches That Occur During a 6-month Period
Status: Completed Condition: Migraine With or Without Aura; Migraine Disorders; Migraine, Acute; Migraine Headaches

Naproxen in Preventing DNA Mismatch Repair Deficient Colorectal Cancer in Patients With Lynch Syndrome
Status: Recruiting Condition: Precancerous Condition

A Pharmacokinetic (PK) Study Evaluating Naproxen and Esomeprazole Plasma Levels
Status: Completed Condition: Arthritis

Influence of Naproxen on Heterotropic Bone Formation Following Hip Arthroscopy
Status: Active, not recruiting Condition: Heterotopic Ossification

Trial of Naproxen to Evaluate Various Methods of Measuring Analgesic Effect in Osteoarthritis Pain of the Knee
Status: Recruiting Condition: Osteoarthritis, Knee

Comparison Study of a New Combination of 2 Marketed Medications (Esomeprazole and Naprosyn) Versus Naprosyn Alone
Status: Completed Condition: Healthy

Pharmacokinetics Study Comparing Naproxen Sodium Extended Release and Naprelan
Status: Completed Condition: Pharmacokinetics

Oral Bioequivalence Study of PL 3100 and Naproxen in Healthy Adults
Status: Completed Condition: Healthy Volunteers

Naproxen for the Prevention of HO After Complex Elbow Trauma
Status: Withdrawn Condition: Heterotopic Ossification

Evaluating PN 400 (VIMOVO) in Reducing Gastric Ulcers Compared to Non-steroidal Antiinflammatory Drug (NSAID) Naproxen
Status: Completed Condition: Gastric Ulcer

Courtesy of ClinicalTrials.org
See more clinical trials for this drug
Glossary
Applicant Tradename Generic Name Dosage NDA Approval Date Type RLD Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Almatica Pharma Inc
NAPRELAN
naproxen sodium
TABLET, EXTENDED RELEASE;ORAL020353Jan 5, 1996RXNo5,637,320<disabled><disabled>
Almatica Pharma Inc
NAPRELAN
naproxen sodium
TABLET, EXTENDED RELEASE;ORAL020353Jan 5, 1996RXYes5,637,320<disabled><disabled>
This preview shows a limited data set
Complete access is available with a Subscription
first patents previous patents next patents last patents

Export unavailable in trial.
Subscribe for complete access.

« Back to Dashboard

DrugPatentWatch Archives

You are viewing the current data set
Select a link below to view the archives:

 2000  2001  2002  2003  2004  2005  2006  2007  2008  2009 
 2010  2011  2012  2013 

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors.

Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided information. There is no warranty that the information contained herein is error free. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Connect with Social Media:

Follow DrugPatentWatch on Twitter Connect with DrugPatentWatch on Linkedin Drug Patents on LinkedIn

Copyright © 2002-2014 thinkBiotech LLC. ISSN: 2162-2639

Other thinkBiotech sites: BiotechUBiotechBlogJournal of Commercial Biotechnology

`abc